| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of
*
Surgery and
Pathology and
Transplantation Biology Research Center, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114
Much evidence supports the conclusion that immunological responses to donor-specific incompatibilities are a major factor in producing "chronic" transplant rejection, including the arteriopathy (atherosclerosis) commonly present. Our experiments explored the effects of altered immunological responsiveness to these Ags on the formation of arteriopathy in transplanted mouse hearts. Specific immunological nonreactivity, or tolerance, was induced either by neonatal administration of allogeneic spleen cells (from F1 donors between class I-mismatched donor and recipient strains), resulting in "classical" immunological tolerance, or by bone marrow infusion to suitably prepared adult recipients, either fully MHC mismatched or class I mismatched, yielding "mixed chimerism." Both approaches obviated systemic graft-versus-host effects. In both groups, donor-specific skin grafts survived perfectly and donor cell chimerism persisted. Specific Abs were undetectable in all recipients. Most transplants to either group of tolerant recipients developed striking vasculopathy in their coronary arteries (12 of 15 in neonatal tolerance and 15 of 23 in mixed chimeras). Neointimal infiltrates included CD4 and CD8 T cells and macrophages. Only 2 of 29 contemporary isotransplants showed any evidence of vasculopathy. Recipients essentially incapable of T and B cell responses (C.B-17/SCID and RAG1-/-) were also used. Transplants into these animals developed vasculopathy in 16 of 31 instances. Accordingly, in this setting, vasculopathy develops in the presence of H-2 gene-determined incompatibility even with minimal conventional immune reactivity. Perhaps innate responsiveness, that could include NK cell activity, can create such arteriopathic lesions. More evidence is being sought regarding this process.
This article has been cited by other articles:
|
|
 |
|
  J. N. Beilke and R. G. Gill Frontiers in Nephrology: The Varied Faces of Natural Killer Cells in Transplantation Contributions to Both Allograft Immunity and Tolerance J. Am. Soc. Nephrol., August 1, 2007; 18(8): 2262 - 2267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Forman, E.-S. Kang, C. Tian, J. Paez-Cortez, and J. Iacomini Induction of Alloreactive CD4 T Cell Tolerance in Molecular Chimeras: A Possible Role for Regulatory T Cells J. Immunol., March 15, 2006; 176(6): 3410 - 3416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Uehara, C. M. Chase, W. H. Kitchens, H. S. Rose, R. B. Colvin, P. S. Russell, and J. C. Madsen NK Cells Can Trigger Allograft Vasculopathy: The Role of Hybrid Resistance in Solid Organ Allografts J. Immunol., September 1, 2005; 175(5): 3424 - 3430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. I. Skaro, R. S. Liwski, J. Zhou, E. L. Vessie, T. D.G. Lee, and G. M. Hirsch CD8+ T cells mediate aortic allograft vasculopathy by direct killing and an interferon-{gamma}-dependent indirect pathway Cardiovasc Res, January 1, 2005; 65(1): 283 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Metzler, P. Gfeller, M. Bigaud, J. Li, G. Wieczorek, C. Heusser, P. Lake, and A. Katopodis Combinations of Anti-LFA-1, Everolimus, Anti-CD40 Ligand, and Allogeneic Bone Marrow Induce Central Transplantation Tolerance through Hemopoietic Chimerism, Including Protection from Chronic Heart Allograft Rejection J. Immunol., December 1, 2004; 173(11): 7025 - 7036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Vassalli, S. Fleury, J. Li, J.-J. Goy, L. Kappenberger, and L. K. von Segesser Gene transfer of cytoprotective and immunomodulatory molecules for prevention of cardiac allograft rejection Eur. J. Cardiothorac. Surg., November 1, 2003; 24(5): 794 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Edelman and H. D. Danenberg Rapamycin for Cardiac Transplant Rejection and Vasculopathy: One Stone, Two Birds? Circulation, July 8, 2003; 108(1): 6 - 8. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Herrero-Fresneda, J. Torras, J. M. Cruzado, E. Condom, A. Vidal, M. Riera, N. Lloberas, J. Alsina, and J. M. Grinyo Do Alloreactivity and Prolonged Cold Ischemia Cause Different Elementary Lesions in Chronic Allograft Nephropathy? Am. J. Pathol., January 1, 2003; 162(1): 127 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Brenner, T. H. Tung, J. N. Jensen, and S. E. Mackinnon The Spectrum of Complications of Immunosuppression: Is the Time Right for Hand Transplantation? J. Bone Joint Surg. Am., October 10, 2002; 84(10): 1861 - 1870. [Full Text] [PDF]
|
|
|
|
|
|
N. Shirasugi, A. B. Adams, M. M. Durham, A. E. Lukacher, H. Xu, P. Rees, S. R. Cowan, M. A. Williams, T. C. Pearson, and C. P. Larsen Prevention of Chronic Rejection in Murine Cardiac Allografts: A Comparison of Chimerism- and Nonchimerism-Inducing Costimulation Blockade-Based Tolerance Induction Regimens J. Immunol., September 1, 2002; 169(5): 2677 - 2684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Herskowitz and A. A. Ansari Are we clear about the mechanisms by which biopsy evidence of interstitial fibrosis following cardiac transplantation helps predict late post-transplant coronary artery disease? J. Am. Coll. Cardiol., March 20, 2002; 39(6): 978 - 980. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
